EP Patent

EP4096630A1 — Topical roflumilast formulation having improved delivery and plasma half-life

Assigned to Arcutis Biotherapeutics Inc · Expires 2022-12-07 · 3y expired

What this patent protects

The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast compo…

USPTO Abstract

The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol monoethyl ether, and/or hexylene glycol.

Drugs covered by this patent

Patent Metadata

Patent number
EP4096630A1
Jurisdiction
EP
Classification
—
Expires
2022-12-07
Drug substance claim
No
Drug product claim
No
Assignee
Arcutis Biotherapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.